Molecular targets such as FGFR2 fusion, IDH1/2 mutation, and HER2 amplification are currently being evaluated for targeted treatment approaches in cholangiocarcinoma (CCA), with most of these strategies still in the clinical investigation phase [71]. Here, ERBB2 is linked to cholangiocarcinoma.